Evidence so far suggests that, despite the greater tau burden in females compared to males, females tend to have a cognitive advantage over men in the preclinical AD stages (i.e., cognitively normal but AD biomarker positive) to early MCI stage of the AD continuum, particularly on tests of verbal memory [7–12]. The gene discussed is MAPT; the disease is Alzheimer disease.